Nicolaou, Sonia T.
Hebditch, Max
Jonathan, Owen J.
Verma, Chandra S.
Warwicker, Jim
Funding for this research was provided by:
Agency for Science, Technology and Research (IDs H17/01/a0/010, IDs H17/01/a0/010)
Engineering and Physical Sciences Research Council (EP/N024796/1, EP/N024796/1)
Article History
Received: 15 March 2021
Accepted: 19 April 2021
First Online: 11 May 2021
Competing interests
: CSV is the founder of Sinopsee Therapeutics and Aplomex. The current work has no conflict with the companies. STN, MH, OJ, and JW declare no conflict of interest.